Invivyd (IVVD) Competitors $1.10 -0.01 (-0.90%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.13 +0.03 (+2.73%) As of 05/22/2026 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IVVD vs. ARDX, NUVB, AGIO, GLUE, and AMLXShould you buy Invivyd stock or one of its competitors? MarketBeat compares Invivyd with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Invivyd include Ardelyx (ARDX), Nuvation Bio (NUVB), Agios Pharmaceuticals (AGIO), Monte Rosa Therapeutics (GLUE), and Amylyx Pharmaceuticals (AMLX). These companies are all part of the "pharmaceutical products" industry. IVVD vs. ARDXIVVD vs. NUVBIVVD vs. AGIOIVVD vs. GLUEIVVD vs. AMLXHow does Invivyd compare to Ardelyx?Invivyd (NASDAQ:IVVD) and Ardelyx (NASDAQ:ARDX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings. Which has more volatility and risk, IVVD or ARDX? Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market. Does the media prefer IVVD or ARDX? In the previous week, Invivyd had 2 more articles in the media than Ardelyx. MarketBeat recorded 13 mentions for Invivyd and 11 mentions for Ardelyx. Invivyd's average media sentiment score of 0.14 beat Ardelyx's score of -0.38 indicating that Invivyd is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has better valuation & earnings, IVVD or ARDX? Invivyd has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$53.43M6.07-$52.49M-$0.31N/AArdelyx$407.32M3.71-$61.60M-$0.23N/A Is IVVD or ARDX more profitable? Ardelyx has a net margin of -13.58% compared to Invivyd's net margin of -138.90%. Ardelyx's return on equity of -38.11% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-138.90% -53.48% -41.56% Ardelyx -13.58%-38.11%-11.85% Do analysts rate IVVD or ARDX? Invivyd presently has a consensus price target of $8.00, suggesting a potential upside of 627.27%. Ardelyx has a consensus price target of $15.70, suggesting a potential upside of 156.96%. Given Invivyd's higher probable upside, equities research analysts clearly believe Invivyd is more favorable than Ardelyx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Ardelyx 1 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.90 Do institutionals & insiders hold more shares of IVVD or ARDX? 70.4% of Invivyd shares are held by institutional investors. Comparatively, 58.9% of Ardelyx shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 5.3% of Ardelyx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. SummaryInvivyd beats Ardelyx on 9 of the 17 factors compared between the two stocks.How does Invivyd compare to Nuvation Bio?Invivyd (NASDAQ:IVVD) and Nuvation Bio (NYSE:NUVB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends. Which has preferable valuation and earnings, IVVD or NUVB? Invivyd has higher earnings, but lower revenue than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$53.43M6.07-$52.49M-$0.31N/ANuvation Bio$143.05M11.50-$204.63M-$0.43N/A Do insiders and institutionals hold more shares of IVVD or NUVB? 70.4% of Invivyd shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 12.3% of Invivyd shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Do analysts recommend IVVD or NUVB? Invivyd currently has a consensus price target of $8.00, suggesting a potential upside of 627.27%. Nuvation Bio has a consensus price target of $12.50, suggesting a potential upside of 164.55%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Nuvation Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Nuvation Bio 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.70 Does the media prefer IVVD or NUVB? In the previous week, Invivyd had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 13 mentions for Invivyd and 5 mentions for Nuvation Bio. Nuvation Bio's average media sentiment score of 0.54 beat Invivyd's score of 0.14 indicating that Nuvation Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nuvation Bio 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk and volatility, IVVD or NUVB? Invivyd has a beta of 0.71, suggesting that its stock price is 29% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.51, suggesting that its stock price is 51% more volatile than the broader market. Is IVVD or NUVB more profitable? Nuvation Bio has a net margin of -102.06% compared to Invivyd's net margin of -138.90%. Nuvation Bio's return on equity of -44.10% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-138.90% -53.48% -41.56% Nuvation Bio -102.06%-44.10%-23.80% SummaryNuvation Bio beats Invivyd on 10 of the 16 factors compared between the two stocks.How does Invivyd compare to Agios Pharmaceuticals?Invivyd (NASDAQ:IVVD) and Agios Pharmaceuticals (NASDAQ:AGIO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability. Is IVVD or AGIO more profitable? Invivyd has a net margin of -138.90% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Invivyd-138.90% -53.48% -41.56% Agios Pharmaceuticals -639.84%-34.11%-31.66% Which has more volatility and risk, IVVD or AGIO? Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.58, suggesting that its share price is 42% less volatile than the broader market. Do analysts recommend IVVD or AGIO? Invivyd presently has a consensus target price of $8.00, suggesting a potential upside of 627.27%. Agios Pharmaceuticals has a consensus target price of $41.56, suggesting a potential upside of 47.67%. Given Invivyd's higher probable upside, equities analysts clearly believe Invivyd is more favorable than Agios Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33Agios Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.45 Do institutionals & insiders hold more shares of IVVD or AGIO? 70.4% of Invivyd shares are held by institutional investors. 12.3% of Invivyd shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has stronger earnings & valuation, IVVD or AGIO? Invivyd has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivyd$53.43M6.07-$52.49M-$0.31N/AAgios Pharmaceuticals$54.03M30.97-$412.78M-$7.25N/A Does the media prefer IVVD or AGIO? In the previous week, Agios Pharmaceuticals had 4 more articles in the media than Invivyd. MarketBeat recorded 17 mentions for Agios Pharmaceuticals and 13 mentions for Invivyd. Agios Pharmaceuticals' average media sentiment score of 0.55 beat Invivyd's score of 0.14 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryInvivyd and Agios Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.How does Invivyd compare to Monte Rosa Therapeutics?Monte Rosa Therapeutics (NASDAQ:GLUE) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends and media sentiment. Does the media favor GLUE or IVVD? In the previous week, Invivyd had 10 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 13 mentions for Invivyd and 3 mentions for Monte Rosa Therapeutics. Invivyd's average media sentiment score of 0.14 beat Monte Rosa Therapeutics' score of 0.00 indicating that Invivyd is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer GLUE or IVVD? Monte Rosa Therapeutics currently has a consensus price target of $32.50, indicating a potential upside of 72.78%. Invivyd has a consensus price target of $8.00, indicating a potential upside of 627.27%. Given Invivyd's higher possible upside, analysts clearly believe Invivyd is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.67Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is GLUE or IVVD more profitable? Invivyd has a net margin of -138.90% compared to Monte Rosa Therapeutics' net margin of -302.69%. Monte Rosa Therapeutics' return on equity of -40.99% beat Invivyd's return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics-302.69% -40.99% -25.94% Invivyd -138.90%-53.48%-41.56% Which has higher valuation and earnings, GLUE or IVVD? Monte Rosa Therapeutics has higher revenue and earnings than Invivyd. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$123.67M12.85-$38.63M-$1.48N/AInvivyd$53.43M6.07-$52.49M-$0.31N/A Do institutionals and insiders believe in GLUE or IVVD? 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Comparatively, 12.3% of Invivyd shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has more risk and volatility, GLUE or IVVD? Monte Rosa Therapeutics has a beta of 1.62, indicating that its share price is 62% more volatile than the broader market. Comparatively, Invivyd has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market. SummaryMonte Rosa Therapeutics beats Invivyd on 9 of the 16 factors compared between the two stocks.How does Invivyd compare to Amylyx Pharmaceuticals?Amylyx Pharmaceuticals (NASDAQ:AMLX) and Invivyd (NASDAQ:IVVD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has more volatility and risk, AMLX or IVVD? Amylyx Pharmaceuticals has a beta of -0.11, suggesting that its share price is 111% less volatile than the broader market. Comparatively, Invivyd has a beta of 0.71, suggesting that its share price is 29% less volatile than the broader market. Do analysts rate AMLX or IVVD? Amylyx Pharmaceuticals currently has a consensus target price of $23.00, indicating a potential upside of 69.37%. Invivyd has a consensus target price of $8.00, indicating a potential upside of 627.27%. Given Invivyd's higher possible upside, analysts plainly believe Invivyd is more favorable than Amylyx Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amylyx Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.77Invivyd 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Do insiders and institutionals believe in AMLX or IVVD? 95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Invivyd shares are owned by institutional investors. 12.3% of Amylyx Pharmaceuticals shares are owned by insiders. Comparatively, 12.3% of Invivyd shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to AMLX or IVVD? In the previous week, Invivyd had 11 more articles in the media than Amylyx Pharmaceuticals. MarketBeat recorded 13 mentions for Invivyd and 2 mentions for Amylyx Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.12 beat Invivyd's score of 0.14 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Invivyd 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has preferable valuation & earnings, AMLX or IVVD? Invivyd has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmylyx Pharmaceuticals$87.37M17.28-$144.74M-$1.50N/AInvivyd$53.43M6.07-$52.49M-$0.31N/A Is AMLX or IVVD more profitable? Amylyx Pharmaceuticals has a net margin of 0.00% compared to Invivyd's net margin of -138.90%. Invivyd's return on equity of -53.48% beat Amylyx Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Amylyx PharmaceuticalsN/A -55.69% -50.73% Invivyd -138.90%-53.48%-41.56% SummaryAmylyx Pharmaceuticals beats Invivyd on 9 of the 17 factors compared between the two stocks. Get Invivyd News Delivered to You Automatically Sign up to receive the latest news and ratings for IVVD and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IVVD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IVVD vs. The Competition ExportMetricInvivydMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$324.07M$3.38B$6.43B$12.33BDividend YieldN/A2.26%2.76%5.28%P/E Ratio-3.5518.9321.2825.67Price / Sales6.07320.49553.3682.70Price / CashN/A125.9643.6856.73Price / Book1.597.1110.367.14Net Income-$52.49M$24.45M$3.56B$335.80M7 Day Performance-9.09%3.32%5.12%3.02%1 Month Performance-24.66%2.52%3.54%2.48%1 Year Performance46.96%63.09%34.14%35.08% Invivyd Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IVVDInvivyd1.9883 of 5 stars$1.10-0.9%$8.00+627.3%+47.0%$324.07M$53.43MN/A100Analyst RevisionARDXArdelyx3.0265 of 5 stars$6.61-2.5%$15.70+137.5%+53.9%$1.67B$407.32MN/A90NUVBNuvation Bio3.0306 of 5 stars$4.77-0.5%$12.50+162.3%+104.5%$1.66B$143.05MN/A60AGIOAgios Pharmaceuticals2.9627 of 5 stars$27.99+0.7%$41.56+48.5%-5.6%$1.65B$54.03MN/A390Trending NewsAnalyst RevisionGLUEMonte Rosa Therapeutics1.9937 of 5 stars$20.26+4.5%$32.50+60.4%+373.8%$1.64B$123.67MN/A90 Related Companies and Tools Related Companies ARDX Competitors NUVB Competitors AGIO Competitors GLUE Competitors AMLX Competitors PAHC Competitors IOVA Competitors ABCL Competitors IMTX Competitors PGEN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IVVD) was last updated on 5/24/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredFrom the man who predicted 2008 crash…Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...Porter & Company | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredYour computer is about to become a museum pieceFuturist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredMusk's shopping list: batteries ✓ solar ✓ data ✓ power ___Elon Musk has a clear pattern: when a supplier becomes mission-critical, he acquires it. He bought SolarCity f...Behind the Markets | SponsoredThis small stock could surge when SpaceX goes publicWhen SpaceX goes public, billions in capital won't just flow into one stock - it will flood the entire sector....NXT Wave Research | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Invivyd, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Invivyd With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
